Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Aaron L Boster"'
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1
Externí odkaz:
https://doaj.org/article/0fa2ae77784345bda11b4afff0c00fe1
Autor:
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sharrack, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Alan Jacobs, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee, Darren P. Baker, Ericka M. Bueno, Colin Mitchell, Rebecca L. Orndorff, Valerie P. Zediak
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f74ae046391f8852664dc6fc783f1a
https://hdl.handle.net/10668/14739
https://hdl.handle.net/10668/14739
